Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report

BACKGROUND: Immune checkpoint blockade is developed as standard treatment for non-small cell lung cancer. However immune-related adverse events (irAE) have still unknown complications. Here, we report a patient with lung squamous cell carcinoma who developed neuromyelitis optica spectrum disorder wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Narumi, Yoshitsugu, Yoshida, Ryohei, Minami, Yoshinori, Yamamoto, Yasushi, Takeguchi, Shiori, Kano, Kohei, Takahashi, Kae, Saito, Tsukasa, Sawada, Jun, Terui, Hiroya, Katayama, Takayuki, Sasaki, Takaaki, Ohsaki, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781276/
https://www.ncbi.nlm.nih.gov/pubmed/29361915
http://dx.doi.org/10.1186/s12885-018-3997-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781276/
https://www.ncbi.nlm.nih.gov/pubmed/29361915
http://dx.doi.org/10.1186/s12885-018-3997-2

Ejemplares similares